Terns Pharmaceuticals Reports P-IIa Trial (DUET) Results of TERN-501 for Non-Alcoholic Steatohepatitis
Shots:
- The P-IIa trial evaluating TERN-501 (THR-β agonist) as monotx. or in combination with TERN-101 (liver-distributed farnesoid X receptor agonist) in 160 patients
- The trial mets their 1EPs & 2EPs i.e., TERN-501 (3 & 6mg) monotx. showed dose-dependent MRI-PDFF reductions with mean relative liver fat content reduction of 45% vs 4% in 6mg at 12wk., >30% MRI-PDFF reduction in (1/3/6mg) were 26%/39%/64% vs 4%
- TERN-501 (6mg) monotx. showed a reduction in 2EPs of a mean change in cT1, trends toward improvement in plasma lipid parameters, and was well-tolerated with no gastrointestinal & no CV safety signals. The combination therapy resulted in an improvement in MRI-PDFF mean relative change (6mg of TERN-501 combo) and >30% MRI-PDFF responder rate (3 & 6 mg of TERN-501 combo) over TERN-501 monotx. at 12wk.
Ref: GlobeNewswire | Image: Terns
Related News:- CAGE Bio Reports P-II Study Results of CGB-500 for the Treatment of Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
